Emtricitabine
- Generic Name
- Emtricitabine
- Brand Names
- Atripla, Biktarvy, Complera, Descovy, Emtriva, Genvoya, Odefsey, Stribild, Truvada
- Drug Type
- Small Molecule
- Chemical Formula
- C8H10FN3O3S
- CAS Number
- 143491-57-0
- Unique Ingredient Identifier
- G70B4ETF4S
- Background
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults or combined with tenofovir alafenamide for the prevention of HIV-1 infection in high risk adolescents and adults. Emtricitabine is a cytidine analogue. The drug works by inhibiting HIV reverse transcriptase, preventing transcription of HIV RNA to DNA.
Emtricitabine was granted FDA approval on 2 July 2003.
- Indication
Emtricitabine is indicated in combination with other medications for the treatment of HIV-1 infections; treatment of HIV-1 infections in pediatric patients 25-35kg, treatment of HIV-1 infections in adult patients ≥35kg, for pre exposure prophylaxis of HIV-1 in adolescent and adult patients excluding those who have receptive vaginal sex; treatment of HIV-1 infections in pediatric and adult patients ≥17kg, pre exposure prophylaxis in adolescents and adults ≥35kg; treatment of HIV-1 in patients ≥12 years and ≥35kg; treatment of HIV-1 in patients weighing ≥35kg; treatment of HIV-1 in patients weighing ≥25kg; and treatment of HIV-1 in patients weighing ≥40kg.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- Pre-Exposure Prophylaxis (PrEP)
A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy
- Conditions
- HIV Infections
- First Posted Date
- 2005-01-26
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 6
- Registration Number
- NCT00102206
- Locations
- 🇺🇸
Columbia IMPAACT CRS, New York, New York, United States
🇺🇸Chicago Children's CRS, Chicago, Illinois, United States
🇺🇸SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States
NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission
- Conditions
- HIV Infections
- Interventions
- Drug: EmtricitabineDrug: Emtricitabine/Tenofovir disoproxil fumarateDrug: NevirapineDrug: Lopinavir/RitonavirDrug: Tenofovir disoproxil fumarate
- First Posted Date
- 2004-08-06
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 745
- Registration Number
- NCT00089505
- Locations
- 🇿🇦
University of Witwatersrand, Johannesburg, South Africa
🇧🇼The Gaborone BHP Study Clinic, Bontleng, Gaborone, Botswana
🇿🇲Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia
Three Month Course of Anti-HIV Medications for People Recently Infected With HIV
- Conditions
- HIV Infections
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
- Conditions
- HIV Infections
- Interventions
- Drug: EfavirenzDrug: AtazanavirDrug: Didanosine (enteric-coated)Drug: Lamivudine/ZidovudineDrug: Emtricitabine/Tenofovir disoproxil fumarateDrug: Emtricitabine
- First Posted Date
- 2004-06-08
- Last Posted Date
- 2018-10-10
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 1571
- Registration Number
- NCT00084136
- Locations
- 🇺🇸
University of Texas, Galveston, Galveston, Texas, United States
🇲🇼College of Med. JHU CRS, P.O. Box 1131, Blantyre, Malawi
🇿🇼UZ-Parirenyatwa CRS, AIDS Research Unit P.O. Box A178, Harare, Zimbabwe
Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2003-01-20
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 19
- Registration Number
- NCT00051831
- Locations
- 🇺🇸
University of Colorado Hospital CRS, Aurora, Colorado, United States
🇺🇸Massachusetts General Hospital ACTG CRS, Boston, Massachusetts, United States
🇺🇸Washington U CRS, Saint Louis, Missouri, United States
Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects
- Conditions
- HIV Infections
- First Posted Date
- 2002-08-19
- Last Posted Date
- 2006-07-27
- Lead Sponsor
- Abbott
- Target Recruit Count
- 200
- Registration Number
- NCT00043966
- Locations
- 🇺🇸
Phoenix Body Positive, Phoenix,, Arizona, United States
🇺🇸Akron Infectious Disease, Inc., Akron, Ohio, United States
🇺🇸Donna E. Sweet, MD, Wichita,, Kansas, United States
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Conditions
- HIV Infections
- Interventions
- Drug: darunavir/ritonavir dosage #1Drug: TAF w/cobicistatDrug: TAF w/cobicistat or ritonavirDrug: tenofovir alafenamide fumarate (TAF)Drug: elvitegravir/cobicistatDrug: darunavir/cobicistatDrug: atazanavir/cobicistatDrug: lopinavir/ritonavir dosage #1Drug: atazanavir/ritonavir/tenofovir dosage #1Drug: lopinavir/ritonavir dosage #2Drug: indinavir/ritonavir dosage #1Drug: fosamprenavir/ritonavirDrug: atazanavir/ritonavir dosage #1Drug: didanosine delayed release (Videx® EC)Drug: emtricitabineDrug: nelfinavir dosage #1Drug: tipranavir/ritonavirDrug: etravirineDrug: darunavir/ritonavir dosage #4Drug: indinavir/ritonavir dosage #2Drug: rilpivirineDrug: ethambutolDrug: efavirenzDrug: raltegravirDrug: dolutegravirDrug: kanamycinDrug: nevirapineDrug: amprenavirDrug: abacavirDrug: tenofovirDrug: maravirocDrug: nelfinavir dosage #2Drug: darunavir/ritonavir dosage #2Drug: lopinavir/ritonavir dosage #3Drug: lopinavir/ritonavir dosage #4Drug: tenofovir/atazanavir/ritonavir dosage #2Drug: atazanavir/ritonavir dosage #2Drug: rifampicinDrug: amikacinDrug: etonogestrel implantDrug: darunavir/ritonavir dosage #3Drug: capreomycinDrug: ethinyl estradiolDrug: isoniazidDrug: moxifloxacinDrug: levoflaxacinDrug: pyrazinamideDrug: ofloxacinDrug: ethionamide/prothionamideDrug: terizidone/cycloserineDrug: para-aminosalicylic acid (PAS)Drug: high dose INHDrug: bedaquilineDrug: clofazamineDrug: delamanidDrug: linezolidDrug: pretomanid
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2022-07-22
- Target Recruit Count
- 1578
- Registration Number
- NCT00042289
- Locations
- 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇿🇦Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa
🇺🇸Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States
A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation
- Conditions
- HIV Infections
- First Posted Date
- 2002-05-13
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 402
- Registration Number
- NCT00036452
- Locations
- 🇺🇸
The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States
🇺🇸MetroHealth CRS, Cleveland, Ohio, United States
🇺🇸Pitt CRS, Pittsburgh, Pennsylvania, United States
Comparing FTC and Lamivudine in HIV-Infected Patients on a Stable Anti-HIV Drug Combination
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Triangle Pharmaceuticals
- Target Recruit Count
- 390
- Registration Number
- NCT00002416
- Locations
- 🇺🇸
Dr Robert Wallace, St. Petersburg, Florida, United States
🇺🇸North Shore Univ Hosp, Great Neck, New York, United States
The Safety and Effectiveness of 524W91
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 18
- Registration Number
- NCT00002335
- Locations
- 🇺🇸
ViRx Inc, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.